Perispinal etanercept stroke trial design: PESTO and beyond

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trial Design

Background:

• Perispinal etanercept (PSE) targets chronic neuroinflammation to improve stroke recovery.
• Extensive scientific evidence and clinical experience support PSE's potential benefits.

Purpose of the Study:

• To provide guidance for designing future randomized clinical trials (RCTs) of PSE for stroke recovery.
• To align future trial designs with current FDA recommendations.

Main Methods:

• Designing future PSE RCTs requires expertise in perispinal delivery and understanding of enriched study populations.
• Key design elements include a clear research question, prospective enrichment for a homogeneous study population, and appropriate outcome measures.
• Minimizing placebo responders and using validated outcome measures are crucial for reliable results.

Main Results:

• The PESTO trial's design flaws highlight the importance of specific elements for valid PSE efficacy conclusions.
• SF-36 is not validated for PSE trials and is unsuitable as a primary outcome measure.

Conclusions:

• Future PSE RCTs must incorporate specific design elements to yield reliable conclusions on efficacy.
• Careful consideration of study population, outcome measures, and delivery expertise is essential for successful PSE trials.